106,654 Shares in Progyny, Inc. $PGNY Purchased by Empowered Funds LLC

Empowered Funds LLC acquired a new stake in Progyny, Inc. (NASDAQ:PGNY) in the first quarter, Holdings Channel reports. The fund acquired 106,654 shares of the company’s stock, valued at approximately $1,811,000.

Several other institutional investors have also made changes to their positions in the stock. Caitong International Asset Management Co. Ltd acquired a new stake in Progyny during the fourth quarter worth approximately $25,000. Hantz Financial Services Inc. raised its holdings in Progyny by 79.4% in the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after acquiring an additional 742 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in Progyny in the 2nd quarter valued at $77,000. Quarry LP lifted its position in shares of Progyny by 2,004.1% during the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after acquiring an additional 3,427 shares during the period. Finally, New Age Alpha Advisors LLC bought a new stake in shares of Progyny during the 4th quarter valued at $94,000. 94.93% of the stock is currently owned by institutional investors.

Trending Headlines about Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Second-quarter adjusted earnings were $0.55 per share, well above the reported consensus estimates of $0.33 and $0.51, and up from $0.19 a year earlier. Revenue reached $350.5 million, exceeding the $348.6 million consensus estimate and rising 5.3% year over year. Progyny, Inc. Announces Second Quarter 2026 Results
• Positive Sentiment: Progyny raised or reaffirmed a favorable full-year outlook, forecasting 2026 earnings of $2.04–$2.10 per share, above the $1.86 analyst consensus. Full-year revenue guidance of approximately $1.4 billion was broadly in line with expectations. Progyny Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: The quarter showed improved profitability, with reported net margin of 5.23% and return on equity of 13.34%, potentially supporting the company’s earnings trajectory. Progyny Earnings Report and Conference Call
• Neutral Sentiment: Third-quarter EPS guidance of $0.50–$0.52 exceeded the $0.47 consensus, indicating continued earnings strength.
• Negative Sentiment: Third-quarter revenue guidance of $335 million–$345 million fell below the $350.2 million analyst estimate. The softer near-term top-line outlook may have outweighed the earnings beats, particularly with PGNY trading at a relatively elevated valuation and near its 12-month high. Progyny Q2 CY2026 Results and Stock Reaction

Progyny Price Performance

Shares of Progyny stock opened at $30.21 on Friday. The company’s 50 day moving average price is $29.02 and its two-hundred day moving average price is $23.40. The firm has a market capitalization of $2.37 billion, a P/E ratio of 39.23, a P/E/G ratio of 2.49 and a beta of 1.01. Progyny, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $33.06.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The company had revenue of $350.51 million during the quarter, compared to the consensus estimate of $348.63 million. During the same period in the prior year, the business earned $0.19 earnings per share. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, analysts expect that Progyny, Inc. will post 1.19 earnings per share for the current year.

Progyny announced that its board has approved a stock repurchase program on Tuesday, May 26th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 10.3% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling at Progyny

In other Progyny news, Director Cheryl Scott sold 7,439 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $26.39, for a total value of $196,315.21. Following the completion of the transaction, the director directly owned 19,772 shares in the company, valued at approximately $521,783.08. This trade represents a 27.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kevin K. Gordon sold 5,500 shares of Progyny stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $24.99, for a total value of $137,445.00. Following the sale, the director directly owned 9,318 shares in the company, valued at $232,856.82. The trade was a 37.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 36,916 shares of company stock worth $939,875 over the last three months. 9.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on PGNY. Weiss Ratings upgraded Progyny from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, June 26th. Canaccord Genuity Group upped their price objective on shares of Progyny from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Barclays reiterated an “equal weight” rating and set a $34.00 price objective (up from $27.00) on shares of Progyny in a research note on Tuesday, July 28th. KeyCorp raised their target price on shares of Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Finally, Zacks Research raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Progyny has an average rating of “Moderate Buy” and a consensus price target of $33.25.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.